To our knowledge, complement modulating drug GL-0719 has a unique profile among complement drugs in development. GL-0719 does each of the following:

  • Inhibits both the classical and MBL complement pathways
  • Increases anti-inflammatory molecules
  • Decreases opsonin binding

GL-0719 is not an antibody but rather an Fc fusion protein that avidly binds complement C1q untethered to a cell. This feature is unique among complement modulating drug candidates.

Because GL-0719 works upstream in the complement pathway, it is expected to be useful not only in diseases that form downstream MAC but also in diseases where the opsonins C1q, C4b, C3b, and iC3b target cells for destruction by phagocytosis. Examples of such opsonin-mediated conditions include the hemolytic anemias, polymyositis, myasthenia gravis, and the approximately 20% of Paroxysmal Nocturnal Hemoglobinuria patients that do not adequately respond to C5 inhibitors such as eculizumab.